The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to
4.7 (99) In stock
The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to all
A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer
Gregory J. Riely's research works
Targeted therapy for rare lung cancers: Status, challenges, and prospects - ScienceDirect
Monika DAVARE, Professor (Associate), PhD
Monika DAVARE, Professor (Associate), PhD
A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials - ScienceDirect
Inna Khodos's research works Memorial Sloan Kettering Cancer
